SCHEMBL1339515

SCHEMBL1339515

Cn1c(=O)c(-c2ccc(Cl)cc2Cl)cc2c3cc(-c4nc(CCl)cs4)ccc3[nH]c21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GFER P55789 1/20 0.43
▸ SHMT1 P34896 5/20 0.38
▸ SHMT2 P34897 4/20 0.38
▸ KDM4E B2RXH2 6/20 0.38
▸ TDP1 Q9NUW8 4/20 0.38
▸ ALDH1A1 P00352 4/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ EIF4E P06730 1/20 0.37
▸ RAB9A P51151 4/20 0.36
▸ NPC1 O15118 3/20 0.36
▸ POLB P06746 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ CRHBP P24387 1/20 0.36
▸ CRHR2 Q13324 1/20 0.36
▸ MAPT P10636 2/20 0.35
▸ CNR1 P21554 2/20 0.35
▸ CNR2 P34972 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1339448 0.92 SHMT1 (0.38) SHMT1SHMT2KDM4EL3MBTL1LMNA
SCHEMBL4717962 0.85 GFER (0.42) GFERSHMT1SHMT2KDM4ETDP1
SCHEMBL1338957 0.83 GFER (0.44) GFERSHMT1SHMT2KDM4ETDP1
SCHEMBL1339352 0.81 TLR8 (0.39) CNR1CNR2
SCHEMBL1336854 0.81 PARP1 (0.42) KDM4EALDH1A1L3MBTL1EIF4ERAB9A
SCHEMBL1338065 0.81 PARP1 (0.41) KDM4EALDH1A1EIF4ERAB9ANPC1
SCHEMBL1338628 0.80 HPSE (0.39) KDM4EEIF4ERAB9ANPC1SMN1; SMN2
SCHEMBL1338675 0.76 CNR1 (0.37) CNR1CNR2
SCHEMBL1338440 0.76 MAP2 (0.45) POLBCNR1CNR2
SCHEMBL1339374 0.75 CNR1 (0.38) KDM4EALDH1A1POLBGAACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 GFER 2646/4885SHMT1 1498/4885SHMT2 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback